Complete AI Training
Start for Free

Your job's AI kit

Get your AI kit

Tell us who you are and what you do. We show you your kit right away and email you the link: skills, prompts, AI agents, MCP servers and courses for your job.

500+ jobs ready, and we make a kit for any other job. No payment needed to look.

Share

AI news ·

Ant Group's MaYi A Fu goes mainstream: 15M users, stocks rally, hospital AI rollouts across China, and an IPO on the way

Ant's MaYi A Fu is surging-#3 on the App Store, 15M MAU, and 5M+ daily health queries as funds pile in. For care leaders: link APIs, measure conversion, prep data governance.

Ant Group's "MaYi A Fu" AI Health App Goes Viral - What Healthcare Leaders Should Do Next

Published: December 24, 2025 * Reading time: 2 minutes

Ant Group's upgraded AI health app, MaYi A Fu, has broken out since its December 15 release. It reached #3 on Apple's App Store, crossed 15 million monthly active users, handles 5+ million daily health queries, and posted an 83% Q3 MAU growth rate versus an industry average of 13.5%.

Healthcare leaders should review strategic implications for delivery, operations, and partnerships: AI for Executives & Strategy.

The momentum isn't just consumer buzz. The Wind AI Healthcare Index rose for three straight sessions after launch. As of December 23, Huakang Jieyi jumped 34%+, Jiahe Meikang 14%+, and Chutian Technology 8%+.

Why this matters for care delivery

MaYi A Fu centers on AI health companionship, Q&A, and services; see practical use cases and deployment patterns in AI for Healthcare. With Ant's payments and insurance rails, it points to a practical medical + pharma + insurance closed loop that can route users from chat to transaction to follow-up.

This shifts AI from a single feature to a front door for consumer health: intake, triage, adherence, and chronic condition support-then handoff to offline care when needed. For health systems and payers, it's a new access channel with measurable conversion and cost metrics.

Signals you should track

  • Hospital infrastructure: China's top 100 hospitals have deployed large models; vendors like Yunzhisheng and iFlytek Medical are embedding AI across full diagnostic workflows.
  • AI drug discovery: Insilico Medicine targets a Hong Kong listing on December 30; its platform has 20+ clinical-stage assets. Insilico Medicine
  • Brokerage views: Everbright Securities highlights AI companionship as a new path to commercialization via Ant's payment/insurance stack. CITIC Securities notes expansion from single products to full scenarios, reaching grassroots clinics and individuals.

Practical moves for providers and payers

  • Integration path: Explore partnership/APIs with MaYi A Fu to route triage, scheduling, and pharmacy orders. Define handoffs to your call centers, clinics, and care teams.
  • Measure what matters: Track cost per resolved query, escalation rate to clinicians, wait time reduction, no-show impact, and adherence uplift.
  • Device connectivity: Prioritize home devices with stable data pipelines (BP cuffs, glucometers, wearables). Use readings to trigger nudges and virtual follow-ups.
  • Data governance: Enforce explicit consent, PHI segregation, model performance review, and audit trails. Maintain human-in-the-loop for high-risk cases.
  • Coverage and billing: Map benefits where Ant's payment/insurance stack can shorten prior auth, co-pay collection, and reimbursement cycles (see AI for Insurance).

Moves for pharma and retail health

  • Traffic capture: Build condition paths from AI chat to pharmacist chat, e-Rx, and local pickup. Optimize for refill adherence and care gaps.
  • Evidence and safety: Use AI-first cohorts for real-world evidence, education, and pharmacovigilance. Keep content medically reviewed and timestamped.

Where investors see opportunity

  • Home medical devices integrated with MaYi A Fu.
  • Offline physical exam providers (e.g., Meinian Health) supplying structured data into AI flows.
  • Pharmaceutical retail and internet medical platforms converting AI traffic to paid services.

Analysts still view AI healthcare as early-but with meaningful upside as usage turns into clinical outcomes and revenue.

What to watch next

  • Conversion from MAU to paid services, pharmacy orders, and insured claims.
  • AI performance in tier-2/3 cities and grassroots settings.
  • Regulatory guidance on data use, safety, and marketing claims.

Resources

  • Ant Group
  • AI courses by job roles (for healthcare teams)
Share